Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06734234 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06734234 · ClinicalTrials.gov record · last posted 2026-07-30

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

StatusActive, Not Recruiting
PhasePhase 1
Started2024-12-11
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is a study where a new drug, called GSK4771261 is being tested. Neither the study doctors, study staff or participants will be aware of what treatment is being given. Part A is testing the new study treatment on healthy people. This is to see if it's safe, what it does to the body, and how the body's defense system responds to it. Part B is similar, but the study treatment will be given to people who have a kidney disease called autosomal dominant polycystic kidney disease (ADPKD).

Protocol amendment history 2 changes detected by DataLookout

2026-07-31
Primary completion pushed: 2027-04-23 → 2027-07-23
2026-07-31
Completion pushed: 2027-04-23 → 2027-07-23
Trial Details
NCT Number NCT06734234
Lead Sponsor GlaxoSmithKline
Conditions Kidney Disease
Enrollment 86 participants
Start Date 2024-12-11
Primary Completion 2027-07-23 (estimated)
Study Completion 2027-07-23 (estimated)
Updated on ClinicalTrials.gov 2026-07-30